Keep­ing pres­sure on Am­gen, Mi­rati draws mixed re­views on lat­est cut of KRAS da­ta

As the close run­ner-up to Am­gen’s Lumakras in the KRAS race, any da­ta cut from Mi­rati’s ada­gra­sib con­tin­ues to draw scruti­ny from an­a­lysts. And the lat­est batch of num­bers from AS­CO is a de­cid­ed­ly mixed bag.

While a quick com­par­i­son sug­gests that ada­gra­sib spurred slight­ly more re­spons­es and led to a longer over­all sur­vival than Lumakras among a group of non-small cell lung can­cer pa­tients, its du­ra­tion of re­sponse ap­pears short­er and the safe­ty pro­file con­tin­ues to spark con­cern.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN